top of page
  • Recruiting

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

Updated: May 23, 2022

PRISM High Risk Smoldering Multiple Myeloma

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)


prism smoldering myeloma

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.


The names of the study drugs involved in this study are:

Daratumumab (also called Darzalex Faspro)

Bortezomib (also called Velcade)

Lenalidomide (also called Revlimid)

Dexamethasone


Sponsor:

Omar Nadeem


Collaborator:

Janssen, LP


Information provided by (Responsible Party):

Omar Nadeem, Dana-Farber Cancer Institute


Locations

United States, Massachusetts

Brigham and Women's Hospital Recruiting

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

 

ClinicalTrials.gov Identifier: NCT04775550


Official Title: B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma

First Posted: March 1, 2021


 





 

* Bortezomib (Velcade)

* Lenalidomide (Revlimid)

* Dexamethasone (Decadron)

* Daratumumab (Darzalex)

Comments


Posts Archive
bottom of page